100% of genes strongly recommended by national oncology guidelines are included in the MyRisk Test.
The Foresight® Carrier Screen includes all conditions recommended by the American College of Medical Genetics and Genomics recommendations
Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy
Screening test provides prenatal risk assessment for common genetic conditions in one blood draw without the need for paternal testing
Two Molecular Residual Disease (MRD) studies highlighting clinical data among seven new studies to be shared by Myriad and collaborators
Study suggests that utilizing RiskScore drives breast cancer screening tailored to individual risk
Podium presentation showcases the clinical application of Precise™ MRD
Craig-Hallum Initiates Myriad Genetics Stock with a Buy Rating
Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test
Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration
Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay
Opening plenary session features latest fetal fraction amplification research